| Patient | Wilma Mankiller |
|---|---|
| Date of birth | 1991-11-18 |
| Identifiers | MRN HR-ML052-SYN; SSN (made up) 000-52-4183 |
| Document date | 2026-11-01 |
| Author | Rena Hawkfeather-Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient with six weeks of drooping eyelids, double vision and fatigable weakness while recovering from a car crash: examination, ice pack test, breathing measurements, baseline tests, a pyridostigmine trial, kidney screening, and neuromuscular neurology referral. Concerns: She wants to know why her eyelids droop and her arms give out, after a year of hard recovery; She wants to keep working for her community; She wants care that respects her as a Cherokee woman, close to home where possible, with her own medicine respected. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating | One tablet three times daily | Oral route | 2026-03-09 to 2026-03-23 | completed | S |
| Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before meals | One tablet four times daily while awake | Oral route | 2026-03-23 to 2026-10-12 | completed | S |
| Pyridostigmine bromide 60 mg oral tablet, one tablet three times daily, 30 to 45 minutes before meals | One tablet three times daily | Oral route | 2026-10-12 | active | S |
| Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mg | Once each morning; dose as directed | Oral route | 2026-03-23 to 2026-07-13 | completed | S |
| Prednisone 5 mg oral tablet, tapering from 40 mg each morning by 5 mg every two to three weeks | Once each morning; dose as directed | Oral route | 2026-07-13 | active | S |
| Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) daily | Once daily; dose as directed | Oral route | 2026-05-04 | active | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with food | One tablet daily with food | Oral route | 2026-03-23 | active | S |
| Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Sulfamethoxazole 800 mg / trimethoprim 160 mg oral tablet, one tablet three times a week, while prednisone is 20 mg or more with azathioprine | One tablet on Monday, Wednesday and Friday | Oral route | 2026-05-04 to 2026-10-05 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain | One or two tablets up to three times daily as needed | Oral route | 2025-09-15 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| CT of the chest with contrast: residual thymic tissue appropriate for age, without a mass; no thymoma; healed rib fractures on the right; lungs clear | 2026-03-18 to 2026-03-18 | completed | S |
| Ultrasound of the kidneys: both kidneys enlarged with many cysts (right 14.1 cm, left 14.6 cm); total kidney volume by the ellipsoid method 594 mL, height-adjusted 364 mL/m, Mayo Imaging Class 1B; several small liver cysts; no stones | 2026-03-18 to 2026-03-18 | completed | S |
| Repetitive nerve stimulation at 3 Hz with needle-free surface recording: reproducible decrement of 22 percent in the nasalis and 18 percent in the trapezius, with partial repair after exercise; normal sensory and motor conduction | 2026-03-23 to 2026-03-23 | completed | S |
| Bedside measurement of breathing: negative inspiratory force -70 cm H2O, single-breath count to 32, with the seated FVC | 2026-03-09 to 2026-03-09 | completed | S |
| Advance care planning conversation, about 20 minutes, with her consent | 2026-08-24 to 2026-08-24 | completed | S |
| Robotic thoracoscopic extended thymectomy from the right, with two nights in hospital and no postoperative myasthenic worsening; pathology: thymic follicular hyperplasia, no thymoma | 2026-06-08 to 2026-06-08 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-06-12 | Tdap vaccine, at the hospital after the crash | completed | S |
| 2026-03-23 | Pneumococcal conjugate vaccine PCV20, before immunosuppression | completed | S |
| 2026-03-23 | Recombinant zoster vaccine, dose 1 of 2, before immunosuppression | completed | S |
| 2026-08-24 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
| 2026-10-12 | Inactivated influenza vaccine, this season | completed | S |
| 2026-10-12 | COVID-19 vaccine, mRNA, this season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1979 (1978 in one account) | Near-fatal head-on car crash with about 17 operations, with fractures of the legs, ribs and face | D (CLM-0005) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| She wants to know why her eyelids droop and her arms give out, after a year of hard recovery | active | S |
| She wants to keep working for her community | active | S |
| She wants care that respects her as a Cherokee woman, close to home where possible, with her own medicine respected | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 12.9 on 2026-10-12; Leukocytes [#/volume] in Blood by Automated count 5.4 on 2026-10-12; Platelets [#/volume] in Blood by Automated count 238 on 2026-10-12; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-03-09; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-07-13; Glucose [Mass/volume] in Serum or Plasma 96 on 2026-07-13; Creatinine [Mass/volume] in Serum or Plasma 0.8 on 2026-10-12; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 99 on 2026-10-12; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2026-03-09; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 23 on 2026-10-12; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-07-13; Albumin [Mass/volume] in Serum or Plasma 4.2 on 2026-03-09; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-03-09; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 2026-10-12; Albumin/Creatinine [Mass Ratio] in Urine 16 on 2026-10-12; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 31 on 2026-03-09; Forced vital capacity [Volume] Respiratory system 3.62 on 2026-10-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-08-24; Acetylcholine receptor binding Ab [Moles/volume] in Serum 6.8 on 2026-03-23; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-12; DXA Femur [Z-score] Bone density -0.4 on 2026-05-04; DXA Lumbar spine [Z-score] Bone density -0.7 on 2026-05-04; Total score [AUDIT-C] 0 on 2026-08-24 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected | resolved | confirmed | H53.2 | S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis. |
| Generalized myasthenia gravis, acetylcholine receptor antibody positive, MGFA class IIa, without thymoma; synthetic modern detail linked to her documented myasthenia gravis of 1980 | active | confirmed | G70.00 | S — Synthetic antibody level, electrodiagnosis, class and treatment; the diagnosis less than a year after the crash, and recovery with Cherokee medicine people, surgery and drug therapy, are documented (D). |
| Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged | active | confirmed | Q61.2 | S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic. |
| Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground | active | confirmed | Z87.81 | S — The crash, the operations and the injuries are documented (D); the current function is synthetic. |
| Long-term glucocorticoid therapy for myasthenia gravis, with monitoring of glucose, blood pressure, weight, bone health, mood, sleep, eyes and infection | active | confirmed | Z79.52 | S — Synthetic treatment plan. |
| Azathioprine as steroid-sparing therapy, with blood count and liver test monitoring | active | confirmed | Z79.624 | S — Synthetic treatment plan. |
| Acquired absence of the thymus after robotic extended thymectomy for myasthenia gravis (pathology: thymic follicular hyperplasia, no thymoma) | active | confirmed | Z90.89 | S — Synthetic: recorded after the thymectomy; the sources name surgery among her treatments without saying which. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-09 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-03-09 | Leukocytes [#/volume] in Blood by Automated count | 6.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-09 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-03-09 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-09 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-09 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-45 U/L | Normal | S |
| 2026-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 8-43 U/L | Normal | S |
| 2026-03-09 | Albumin [Mass/volume] in Serum or Plasma | 4.2 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-03-09 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-03-09 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.3 | % | <=5.6% | Normal | S |
| 2026-03-09 | Albumin/Creatinine [Mass Ratio] in Urine | 14 | mg/g | Below 30 mg/g is normal (A1) | Normal | S |
| 2026-03-09 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 31 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-03-09 | Forced vital capacity [Volume] Respiratory system | 3.3 | L | Lower limit of normal about 2.9 L for her age, sex and height | Normal | S |
| 2026-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-03-23 | Acetylcholine receptor binding Ab [Moles/volume] in Serum | 6.8 | nmol/L | 0.02 nmol/L or less is negative | High | S |
| 2026-03-23 | Forced vital capacity [Volume] Respiratory system | 3.25 | L | Lower limit of normal about 2.9 L for her age, sex and height | Normal | S |
| 2026-03-23 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-05-04 | Hemoglobin [Mass/volume] in Blood | 13.2 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-05-04 | Leukocytes [#/volume] in Blood by Automated count | 10.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-04 | Platelets [#/volume] in Blood by Automated count | 284 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-04 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.76 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 105 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 7-45 U/L | Normal | S |
| 2026-05-04 | Forced vital capacity [Volume] Respiratory system | 3.48 | L | Lower limit of normal about 2.9 L for her age, sex and height | Normal | S |
| 2026-05-04 | DXA Femur [Z-score] Bone density | -0.4 | {Z-score} | Above -2.0 is within the expected range for age | Normal | S |
| 2026-05-04 | DXA Lumbar spine [Z-score] Bone density | -0.7 | {Z-score} | Above -2.0 is within the expected range for age | Normal | S |
| 2026-05-04 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-07-13 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-07-13 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-13 | Platelets [#/volume] in Blood by Automated count | 250 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-13 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.79 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-45 U/L | Normal | S |
| 2026-07-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-43 U/L | Normal | S |
| 2026-07-13 | Forced vital capacity [Volume] Respiratory system | 3.4 | L | Lower limit of normal about 2.9 L for her age, sex and height | Normal | S |
| 2026-07-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-12 | Hemoglobin [Mass/volume] in Blood | 12.9 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-10-12 | Leukocytes [#/volume] in Blood by Automated count | 5.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-12 | Platelets [#/volume] in Blood by Automated count | 238 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-10-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 99 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 7-45 U/L | Normal | S |
| 2026-10-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | <=5.6% | Normal | S |
| 2026-10-12 | Albumin/Creatinine [Mass Ratio] in Urine | 16 | mg/g | Below 30 mg/g is normal (A1) | Normal | S |
| 2026-10-12 | Forced vital capacity [Volume] Respiratory system | 3.62 | L | Lower limit of normal about 2.9 L for her age, sex and height | Normal | S |
| 2026-10-12 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-08-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-08-24 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-09 | Body height | 163 | cm | S |
| 2026-03-09 | Body weight | 61.8 | kg | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 23.3 | kg/m2 | S |
| 2026-03-09 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-03-09 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-03-09 | Heart rate | 78 | /min | S |
| 2026-03-09 | Respiratory rate | 16 | /min | S |
| 2026-03-09 | Body temperature | 36.7 | Cel | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-23 | Body height | 163 | cm | S |
| 2026-03-23 | Body weight | 61.6 | kg | S |
| 2026-03-23 | Body mass index (BMI) [Ratio] | 23.2 | kg/m2 | S |
| 2026-03-23 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-03-23 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-03-23 | Heart rate | 76 | /min | S |
| 2026-03-23 | Respiratory rate | 16 | /min | S |
| 2026-03-23 | Body temperature | 36.6 | Cel | S |
| 2026-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-04 | Body height | 163 | cm | S |
| 2026-05-04 | Body weight | 63.9 | kg | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 24.1 | kg/m2 | S |
| 2026-05-04 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-05-04 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-05-04 | Heart rate | 80 | /min | S |
| 2026-05-04 | Respiratory rate | 16 | /min | S |
| 2026-05-04 | Body temperature | 36.6 | Cel | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-13 | Body height | 163 | cm | S |
| 2026-07-13 | Body weight | 64.8 | kg | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2026-07-13 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-07-13 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-07-13 | Heart rate | 74 | /min | S |
| 2026-07-13 | Respiratory rate | 14 | /min | S |
| 2026-07-13 | Body temperature | 36.7 | Cel | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-12 | Body height | 163 | cm | S |
| 2026-10-12 | Body weight | 63.6 | kg | S |
| 2026-10-12 | Body mass index (BMI) [Ratio] | 23.9 | kg/m2 | S |
| 2026-10-12 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-10-12 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-12 | Heart rate | 72 | /min | S |
| 2026-10-12 | Respiratory rate | 14 | /min | S |
| 2026-10-12 | Body temperature | 36.6 | Cel | S |
| 2026-10-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-08-24 | Body height | 163 | cm | S |
| 2026-08-24 | Body weight | 64.2 | kg | S |
| 2026-08-24 | Body mass index (BMI) [Ratio] | 24.2 | kg/m2 | S |
| 2026-08-24 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-08-24 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-24 | Heart rate | 72 | /min | S |
| 2026-08-24 | Respiratory rate | 14 | /min | S |
| 2026-08-24 | Body temperature | 36.6 | Cel | S |
| 2026-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-09 | New patient with six weeks of drooping eyelids, double vision and fatigable weakness while recovering from a car crash: examination, ice pack test, breathing measurements, baseline tests, a pyridostigmine trial, kidney screening, and neuromuscular neurology referral | finished | S |
| 2026-03-23 | Two-week review with the neuromuscular neurology consultation the same day: antibody, nerve stimulation, chest CT and kidney ultrasound results, the diagnosis, and the treatment plan | finished | S |
| 2026-05-04 | Six-week review on pyridostigmine and prednisone: strength, breathing, glucose and blood pressure, bone density, start of azathioprine, and the thymectomy plan | finished | S |
| 2026-07-13 | Review five weeks after thymectomy: recovery, pathology, azathioprine monitoring, the prednisone taper, and kidney care | finished | S |
| 2026-10-12 | Seven-month review: minimal manifestation status, prednisone and pyridostigmine reduction, azathioprine safety, kidney screening, and plans for the year | finished | S |
| 2026-08-24 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Neuromuscular neurology consultation within two weeks for suspected generalized myasthenia gravis: diagnosis, immunotherapy, thymectomy and safety | completed | GL-MG-2020, GL-MG-2016 | S |
| Diagnostic tests: acetylcholine receptor binding antibodies (MuSK antibodies if negative), repetitive nerve stimulation (single-fiber EMG if unclear), CT of the chest with contrast for thymoma, TSH, and seated FVC with negative inspiratory force | completed | GL-MG-2016, GL-MG-2020 | S |
| Safety: pyridostigmine 30 mg three times daily as a trial; warning signs of myasthenic crisis (breathlessness lying flat, weak cough, trouble swallowing, slurred speech) with emergency care the same day; a wallet card and the list of medicines to avoid, including fluoroquinolones, aminoglycosides, macrolides, magnesium by vein, beta-blockers and telithromycin | completed | GL-MG-2016, GL-MGFA-DRUGS | S |
| Kidney care for her hereditary polycystic kidney disease: kidney ultrasound with total kidney volume, eGFR and urine albumin, home blood pressure readings, 2 to 3 liters of water a day spread through the day, less salt, and acetaminophen instead of NSAIDs | completed | GL-KDIGO-ADPKD-2025 | S |
| Culturally safe care: laboratory work at a Cherokee Nation Health Services clinic near her home, results shared with this clinic; time given to explain each test and medicine plainly; her own Cherokee medicine respected, with any plant medicine shared so that interactions can be checked, and nothing further asked | completed | GL-CNHS, GL-MG-2016 | S |
| Immunotherapy: pyridostigmine 60 mg four times daily; prednisone 10 mg each morning rising by 10 mg a week to 40 mg; azathioprine after TPMT activity and hepatitis B and tuberculosis screening, from 50 mg to 150 mg daily; pneumococcal and recombinant zoster vaccines before immunosuppression; no live vaccines | completed | GL-MG-2016, GL-MG-2020, GL-CDC-IMZ-2026 | S |
| Thymectomy: thoracic surgery assessment for robotic extended thymectomy once she is stable, for AChR antibody-positive generalized MG at 34 | completed | GL-MG-2020, GL-MGTX-2016 | S |
| Glucocorticoid safety: calcium and vitamin D, DXA within the first months, glucose and hemoglobin A1c, blood pressure and weight at each visit, sleep and mood, eye examination yearly, and Pneumocystis prophylaxis while prednisone is 20 mg or more with azathioprine | completed | GL-ACR-GIOP-2022, GL-MG-2016 | S |
| Azathioprine monitoring: blood count and liver tests every one to two weeks for the first two months, then every three months | completed | GL-MG-2016 | S |
| Newer targeted therapies (efgartigimod, eculizumab or ravulizumab) kept in reserve for refractory disease or intolerance of standard immunotherapy; complement inhibitors would need meningococcal vaccination first | completed | GL-MG-2020, GL-ADAPT-2021 | S |
| Standing laboratory orders at the Cherokee Nation Health Services clinic near her home for every azathioprine blood test, with results sent to this clinic and a nurse call for each result | completed | GL-CNHS, GL-MG-2016 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| A confirmed diagnosis and treatment plan within three weeks | 2026-03-23 | completed | AChR antibodies, nerve stimulation, chest CT and kidney ultrasound done; generalized MG diagnosed and treatment begun at two weeks | S |
| Minimal manifestation status (MG-ADL 0 to 1) within a year, with prednisone at 7.5 mg or less | 2026-10-12 | active | MG-ADL 7 at diagnosis, 1 at seven months; prednisone 15 mg and still tapering | S |
| No myasthenic crisis, and she knows the warning signs and the medicines to avoid | 2026-10-12 | completed | No crisis; FVC 3.25 to 3.62 L; she carries a wallet card and the list of medicines to avoid | S |
| Kidney health: eGFR and urine albumin yearly, home blood pressure 110/75 mm Hg or lower if it rises above 130/85, 2 to 3 liters of water a day, and no NSAIDs | 2026-10-12 | completed | eGFR normal; urine albumin normal; home blood pressure about 116/74 without medicine | S |
| Return to full-time work for the Cherokee Nation | 2026-10-12 | completed | Back at work full time from the seventh month | S |